Genmab — Januar 2019
-
Celgene raised Revlimid price by 3.5 percent https://www.bloomberg.com/news/articles/2019-01-04/celgene-boosted-price-of-its-top-cancer-drug-on-day-of-mega-deal
-
-
Ditto her i Regstrup.
-
Ret vild med denne overskrift: http://www.proinvestor.com/investornyt/585264/panikkdrevet-ettersporsel-pa-borsene-i-new-york
-
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation - A Network Meta-analysis http://www.haematologica.org/content/early/2019/01/02/haematol.2018.206912
-
Article in Blood Cancer Journal: "Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provices evidence for shared aetiology". Spændende om det på sigt kan føre til noget positivt for DARA, der har et par studier kombineret med Ibrutinib. https://www.nature.com/articles/s41408-018-0162-8
-
bibob...Det er sjældent, at man som investor oplever en situation med så bred efterspørgsel. Det skyldes måske, at rigtig mange aktier er blevet shortet. Kongetallet og dæmpning af frygten for recession fik nok mange til at lukke shortpositioner i en fart. Det kan sagtens forsætte i næste uge.
-
Med mindre at han tweetter om en bilæggelse af handelstriden med Kina.
-
-
Det kan kun glæde mig når jeg kigger på 2018 resultatet hos AQR
https://funds.aqr.com/total-returns -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind